Sharon Tal, Lippin Naama, Yehezkeli Veronika, Dar Nimrod, Belkin Avner, Assia Ehud I
Department of Ophthalmology, Meir Medical Center, Kfar Saba 4428164, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
J Clin Med. 2025 Mar 14;14(6):1972. doi: 10.3390/jcm14061972.
: this study aims to assess the safety of ciliary sulcus-placed hydrophilic acrylic intraocular lenses (IOLs). In this retrospective cohort study, consecutive patients who underwent phacoemulsification with implantation of IOLs into the ciliary sulcus without suture fixation between 2014 and 2016 at the Meir Medical Center were included. Clinical outcomes were compared between one-piece (1P) hydrophilic acrylic IOLs (Seelens AF, Hanita Lenses, Kibbutz Hanita, Israel) and three-piece hydrophobic acrylic IOLs with PMMA haptics (3P) (MA60AC, Alcon Laboratories, USA). Thirty-eight eyes met the inclusion criteria and had ciliary sulcus IOLs implanted, twenty-three eyes with 1P hydrophilic (60.52%) and fifteen (39.47%) with 3P hydrophobic IOLs. Mean follow-up was 47.36 ± 7.25 months for the 1P group and 46.54 ± 9.82 months for the 3P group ( = 0.87). The mean peak IOP was higher in the 3P group ( = 0.038). No differences in the incidence of anterior uveitis or cystoid macula edema (CME) were detected between the groups ( > 0.05). None of the patients in our study developed uveitis, bleeding episodes, or required treatment for increased intraocular pressure, and no patient was diagnosed with uveitis-glaucoma-hyphema (UGH) syndrome. Post-operative corrected distance visual acuity (CDVA) was similar between the groups ( = 0.66). Hydrophilic IOLs can be safely placed in the ciliary sulcus and are non-inferior to the implantation of three-piece hydrophobic IOLs in the sulcus. In our cohort, with an average follow-up of approximately four years, no UGH was diagnosed, and none of the lenses were explanted.
本研究旨在评估睫状沟植入亲水性丙烯酸人工晶状体（IOL）的安全性。在这项回顾性队列研究中，纳入了2014年至2016年期间在梅尔医学中心连续接受超声乳化白内障吸除术并将IOL植入睫状沟且未进行缝线固定的患者。比较了一体式（1P）亲水性丙烯酸IOL（Seelens AF，哈尼塔镜片公司，以色列哈尼塔基布兹）和带有PMMA襻的三件式疏水性丙烯酸IOL（3P）（MA60AC，爱尔康实验室，美国）的临床结果。38只眼符合纳入标准并植入了睫状沟IOL，其中23只眼植入1P亲水性IOL（60.52%），15只眼（39.47%）植入3P疏水性IOL。1P组的平均随访时间为47.36±7.25个月，3P组为46.54±9.82个月（P = 0.87）。3P组的平均眼压峰值较高（P = 0.038）。两组之间前葡萄膜炎或黄斑囊样水肿（CME）的发生率无差异（P>0.05）。本研究中没有患者发生葡萄膜炎、出血事件或需要治疗眼压升高，也没有患者被诊断为葡萄膜炎-青光眼-前房积血（UGH）综合征。两组术后矫正远视力（CDVA）相似（P = 0.66）。亲水性IOL可安全地植入睫状沟，在睫状沟植入时不劣于三件式疏水性IOL。在我们的队列中，平均随访约四年，未诊断出UGH，且没有晶状体被取出。
